Monoclonal antibody:
Treatment of advanced soft tissue sarcoma in
combination with doxorubicin
Potentially hazardous interactions with other drugs
Live vaccines: avoid with olaratumab in combination
with doxorubicin.
Mainly degraded non-specifically by proteolytic enzymes.
